Previous 10 | Next 10 |
home / stock / soltf / soltf news
Sosei Group ( OTCPK:SOLTF ) : 1H net loss of $19.6M More news on: Sosei Group Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
TOKYO and LONDON , Aug. 13, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first half ended 30 June 2020 . The full report can be accessed by clicking here . ...
TOKYO and LONDON , July 16, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen denominated convertible bonds due 2025 that has raised a total of approximatel...
- Once-daily Enerzair ® Breezhaler ® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life in people with uncontrolled asthma 1 - IND/GLY/MF ...
Sosei Group ( OTCPK:SOLTF ): Q1 net loss of $6.9M More news on: Sosei Group Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
TOKYO and LONDON , May 13, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2020 . The full report can be accessed by clicking here . O...
- Sosei Heptares solves structure of the agonist bound orexin OX2 receptor and identifies small molecule binding site using unique StaR ® technology and structure-based approach - New improved insights into the receptor's structure will help optimize the discovery and develo...
- Positive opinion received from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) - Enerzair® Breezhaler® (QVM149) is a once-daily, potential first-in-class inhaled LABA/LAMA/ICS combination for asthma patients in the EU TOKYO and ...
- New program to focus initially on inhibitors of SARS-CoV-2 protease, a protein essential for the viral life cycle - SBDD capabilities will also be contributed to broader discovery collaborations seeking novel drugs against SARS-CoV-2 - All findings to be made ...
Strengthened focus on the execution of the next stage of growth strategy Strategy aims to leverage world-class Platform, Discovery and Early Development capabilities to advance and extend its portfolio of Partnered Programs TOKYO and LONDON , March 25, 2020 /PRNewswire/ ...
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024. The Company will host a live webinar presentation with C...
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million...
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Report for the year ended 31 December 2023. The Annu...